Bavarian Biotech Report 2012/13 - Der Cluster

More documents

Recommendations

Info

Revenues were BayBG, a key equity investor for Proteros, and two new debt financial institutions. The capital will be used for further development, with a particular focus on investment into Proteros' further downstream drug discovery capabilities. Follow-on investments: Capital raised from publicly listed companies slightly declined by 2 % and amounted € 38.4 million for the year 2012. With the capital increase in February 2012, Wilex AG planned to use the gross proceeds of approximately € 9.93 million to finance its ongoing clinical studies as well as to enhance its equity position by exercising 3,201,928 new no-par value bearer shares for € 3.10. By the end of June 2012 4SC AG (Martinsried) announced , that a total of 8,403,510 new no-par value bearer shares with a subscription price of € 1,50 per share were placed with existing shareholders and institutional investors. The company thereby realized gross proceeds in the amount of € 12.6 million. In June, Wilex AG (Munich) exercised 6,460,544 new no-par value bearer share for 3,70 Euro per share. Wilex shareholder dievini Hopp Biotech holding GmbH & Co.KG (Walldorf, Germany) changed its existing loan plus interests with the value of € 7.77 million to 2,100,337 new shares. This represents 32.5 % of the total volume of the capital increase. In total, the company’s equity base reached € 23.9 million. Because of the delisting of some Bavarian companies from the stock exchange - by mergers and acquisitions (like Geneart/Life Technologies and Micromet/Amgen) – the revenues of all Bavarian biotech-SMEs are counted in total (in contrast to previous surveys). According to the 90 % feedback from our questionnaire, total revenues in 2012 for all biotech-SME companies can be estimated at around € 525 million. This represents an increase of about 2 % compared to 2011 revenues. REVENUES ALL BIOTECH SME IN MIO. € 2010 2011 2012 Currently, the roller coaster of external financing is still going downhill in the biotech sector, but there is light at the end of the tunnel: Most of the companies are independent on external financing and the companies performed very well in closing attractive deals, improving revenues or receiving grants. During 2012, the total deal value was approximately € 1 billion – again, one has to add, after the € 1 billion hurdle was already reached in 2011. 470 515 525 Summary In the past years, the Bavarian biotechnology sector has shown its strength despite the economically unstable times and the lack of a vital Venture Capital scene in Germany. It showed stable growth rates almost every year since 2005 in terms of sales and employees. Bavaria can count on an intact technology leadership position which attracts the most famous global companies. The roller coaster ride, which the course of innovation offers to all stakeholders, is neither always going up nor going always down – and Bavaria is still aiming high and reaching out for success! 36
4 Strong Partners for Personalized Medicine Excellent Universities and Research Institutes 350 Life Science Companies World renowned Hospitals Professional Cluster Management www.m4.de 37
Page 2 and 3: We have 80,000 R&D centres like thi
Page 4 and 5: Imprint Editorial staff: Georg Kä
Page 6 and 7: Nanotechnology-based Drugs Patented
Page 8 and 9: Der Schnellüberblick Executive Sum
Page 10 and 11: eine Vielzahl weiterer Niederlassun
Page 12 and 13: Biotechnology: Regional Profiles in
Page 14 and 15: ”Since 1998, more than two billio
Page 16 and 17: Biotechnology is an industry applic
Page 18 and 19: Biotechnology: Science in Bavaria B
Page 20 and 21: CISPM forms an umbrella under which
Page 22 and 23: Facts and Figures 2012 Number of Co
Page 24 and 25: Employment Jobs in Biotechnology an
Page 26 and 27: Products and Pipeline Drug Developm
Page 28 and 29: PHASE II 4SC AG: hepatocellular car
Page 30 and 31: ”The investment of Amgen Research
Page 32: M&A Activity During the year 2012,
Page 35: TUM Fund and Bio M AG. The company
Page 40 and 41: 2bind GmbH BIOTECH DNA & PROTEIN AN
Page 42 and 43: Activaero GmbH MEDTECH Contact: Ber
Page 44 and 45: Affectis Pharmaceuticals AG BIOTECH
Page 46 and 47: AMGEN Research (Munich) GmbH BIOTEC
Page 48 and 49: Contact: Prof. Dr. med. Reinhold P.
Page 50 and 51: Assign International GmbH CRO Conta
Page 52 and 53: Bavarian Nordic GmbH BIOTECH THERAP
Page 54 and 55: Bicoll GmbH BIOTECH THERAPEUTICS &
Page 56 and 57: Biomax Informatics AG BIOTECH BIOIN
Page 58 and 59: Bio-Rad Laboratories GmbH BIOTECH D
Page 60 and 61: Carl Zeiss Microscopy GmbH BIOTECH
Page 62 and 63: Cfm Oskar Tropitzsch e.K. PHARMA &
Page 64 and 65: Clinipace GmbH CRO Contact: Birgit
Page 66 and 67: Contact: Jürgen Schäfer Neuhauser
Page 68 and 69: CROS DE GmbH CRO Contact: Eva Hurst
Page 70 and 71: Data Analysis Solutions DA-SOL GmbH
Page 72 and 73: Dojindo EU GmbH REAGENTS Contact: T
Page 74 and 75: eADMET GmbH BIOTECH BIOINFORMATICS
Page 76 and 77: Entelechon GmbH BIOTECH DNA/PROTEIN
Page 78 and 79: Eurofins Medigenomix GmbH BIOTECH D
Page 80 and 81: Exosome Diagnostics GmbH BIOTECH TH
Page 82 and 83: FGK Representative Service GmbH CRO
Page 84 and 85: GeneArt AG BIOTECH Keywords: Genomi
Page 86 and 87:
Genomatix Software GmbH BIOTECH BIO
Page 88 and 89:
Contact: Dipl.-Ing. Robert Grafina
Page 90 and 91:
Hematris Wound Care GmbH MEDTECH Co
Page 92 and 93:
HTI bio-X GmbH BIOTECH DEVICES & RE
Page 94 and 95:
IKINOWO GmbH BIOTECH THERAPEUTICS &
Page 96 and 97:
immunoGlobe Antikörpertechnik GmbH
Page 98 and 99:
Infors GmbH BIOTECH DEVICES & REAGE
Page 100 and 101:
Contact: Dr. Hermann Schulz Bayerst
Page 102 and 103:
KLIFOVET AG CRO Contact: Dr. Klaus
Page 104 and 105:
LAT GmbH Dr. Tittel Institut für P
Page 106 and 107:
Contact: Dr. Caroline Freye-Minks M
Page 108 and 109:
MedPharmTec-Services CRO Contact: D
Page 110 and 111:
MicroCoat Biotechnologie GmbH BIOTE
Page 112 and 113:
Molecular Networks GmbH BIOTECH BIO
Page 114 and 115:
MWM Biomodels GmbH BIOTECH THERAPEU
Page 116 and 117:
NanoTemper Technologies GmbH BIOTEC
Page 118 and 119:
Contact: Frank Hauerken Zielstattst
Page 120 and 121:
Nuvisan GmbH CRO Contact: Dr. Karl
Page 122 and 123:
P.SS.T Pharma Scientific Services T
Page 124 and 125:
Pelo Biotech GmbH BIOTECH DEVICES &
Page 126 and 127:
PharmaZell Contact: Dr. Wolfgang Bu
Page 128 and 129:
PIKA Weihenstephan GmbH BIOTECH AGR
Page 130 and 131:
PRIONICS DEUTSCHLAND GmbH BIOTECH A
Page 132 and 133:
R&D Biopharmaceuticals GmbH BIOTECH
Page 134 and 135:
Securetec Contact: Dr. Karl Kugelbr
Page 136 and 137:
SIRION BIOTECH GmbH BIOTECH DEVICES
Page 138 and 139:
SuppreMol GmbH BIOTECH THERAPEUTICS
Page 140 and 141:
TopLab GmbH BIOTECH DNA/PROTEIN ANA
Page 142 and 143:
Vaecgene Biotech GmbH BIOTECH THERA
Page 144 and 145:
ViroLogik GmbH BIOTECH THERAPEUTICS
Page 146 and 147:
Wimasis GmbH BIOTECH BIOINFORMATICS
Page 148:
Contact: Ursula Mader Lochhamer Str
Page 152:
LAB RESULTS YOU CAN TRUST CUSTOMIZE
show all

Bavarian Biotech Report 2012/13 - Der Cluster

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?